How Fatty Liver Disease Works—and Why It's Silent
Fatty liver disease (MASLD) affects nearly 40% of adults worldwide yet rarely shows symptoms until serious damage occurs. Here's how fat infiltrates the liver, why the disease progresses silently, and what treatments are finally emerging.
The Epidemic Hiding in Plain Sight
Nearly four in ten adults worldwide carry excess fat in their liver, yet most have no idea. Metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as nonalcoholic fatty liver disease (NAFLD)—has quietly become one of the most common chronic conditions on the planet. Projections suggest 1.8 billion people could have MASLD by 2050, a 42% increase from current levels. Despite those staggering numbers, the disease rarely announces itself until the liver is already scarred.
How Fat Infiltrates the Liver
A healthy liver contains small amounts of fat. MASLD begins when triglycerides—a type of fat molecule—accumulate inside hepatocytes, the liver's workhorse cells. The primary driver is insulin resistance: when cells stop responding efficiently to insulin, the body redirects more fatty acids toward the liver for storage.
Obesity, type 2 diabetes, high blood pressure, and elevated cholesterol all amplify this process. Up to 75% of people with type 2 diabetes also have MASLD, according to the American Diabetes Association. The liver, designed to process fat in small quantities, becomes overwhelmed.
From Fat to Inflammation to Scarring
Not everyone with a fatty liver develops serious problems. In many people, the condition remains stable for years. But in a subset—estimated at 7% to 35% annually—the disease crosses a dangerous threshold into metabolic dysfunction-associated steatohepatitis (MASH).
At this stage, the accumulated fat triggers chronic inflammation. Adipose tissue releases inflammatory mediators like tumor necrosis factor-alpha and interleukin-6, which damage hepatocytes. The liver's repair cells, called hepatic stellate cells, activate and begin depositing collagen—scar tissue—around damaged areas.
Doctors grade this scarring in four fibrosis stages:
- F0–F1: No or minimal scarring; fully reversible with lifestyle changes
- F2: Moderate scarring; the liver still functions well but damage is accumulating
- F3: Advanced fibrosis; significant scarring, though some repair is still possible
- F4: Cirrhosis; irreversible scarring that can lead to liver failure or cancer
Each fibrosis stage lasts roughly seven years on average, meaning the disease typically progresses over decades—silently.
Why It Stays Hidden
MASLD earns its reputation as a "silent" disease because most people experience no symptoms during the early stages. There is no pain, no jaundice, no obvious warning sign. Fatigue and vague abdominal discomfort may appear, but they are easily attributed to other causes. Many cases are discovered incidentally during imaging for unrelated conditions.
Standard liver blood tests can appear normal even when significant fat is present. Diagnosis often requires imaging—typically ultrasound or a specialized MRI—and a liver biopsy remains the gold standard for confirming MASH and staging fibrosis.
Treatment: Lifestyle First, Drugs Emerging
For decades, the only prescription for fatty liver disease was weight loss and exercise. Losing 5% to 10% of body weight can significantly reduce liver fat and even reverse early-stage fibrosis. No drug existed to treat the condition directly.
That changed in March 2024, when the U.S. Food and Drug Administration granted accelerated approval to resmetirom (brand name Rezdiffra), the first drug specifically approved for MASH with moderate to advanced fibrosis. Resmetirom activates a thyroid hormone receptor in the liver called THR-β, which helps reduce fat accumulation. In clinical trials, 24% to 36% of patients on the drug achieved MASH resolution without worsening fibrosis, compared to 9% to 13% on placebo.
GLP-1 receptor agonists like semaglutide—already approved for diabetes and obesity—are also showing promise. Research published in April 2026 found that semaglutide acts directly on liver cells to improve function, independent of weight loss.
A Growing Global Challenge
As obesity and diabetes rates climb worldwide, MASLD is projected to become the leading cause of liver transplants and a major driver of liver cancer. The disease already affects more than 122 million adults in the United States alone. Awareness remains the biggest hurdle: most people with fatty livers do not know they have one, and routine screening is not yet standard practice.
Understanding how the disease works—and recognizing its risk factors early—may be the most effective medicine of all.
